Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952287 | 1.00 | CYP2A6 (1.00) | CYP2A6ALDH1A1DYRK1APTPRCPTPN6 | |
| SCHEMBL1894396 | 0.83 | CYP2A6 (0.71) | CYP2A6ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL9432076 | 0.83 | CYP2A6 (0.70) | CYP2A6ALDH1A1DYRK1APTPRCPTPN6 | |
| SCHEMBL2825533 | 0.81 | CYP2A6 (0.67) | CYP2A6ALDH1A1DYRK1ACA2CA12 | |
| SCHEMBL6598547 | 0.79 | CYP2A6 (0.66) | CYP2A6ALDH1A1DYRK1APTPRCPTPN6 | |
| SCHEMBL13177010 | 0.79 | CYP2A6 (0.66) | CYP2A6ALDH1A1DYRK1APTPRCPTPN6 | |
| SCHEMBL27727596 | 0.79 | CYP2A6 (0.66) | CYP2A6ALDH1A1DYRK1APTPRCPTPN6 | |
| SCHEMBL20759181 | 0.76 | CYP2A6 (0.57) | CYP2A6CA2CA12RAB9A | |
| SCHEMBL16693049 | 0.75 | CYP2A6 (0.59) | CYP2A6ALDH1A1DYRK1APTPRCPTPN6 | |
| SCHEMBL9798820 | 0.73 | CYP2A6 (0.57) | CYP2A6PTPRCPTPN6PTPN11PTPN22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106459062-A | Substituted [1,2,4] triazolo [1,5-a ] pyrimidin-7-yl compounds as PDE2 inhibitors | 达特神经科学(开曼)有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-104774319-B | Bis(benzothiophene) ethylene polymers and preparation method and application thereof | 中国科学院化学研究所 | 2017-02-01 | — | — | CN | claimed |
| CN-104774319-A | Bis(benzothiophene) ethylene polymers and preparation method and application thereof | CHINESE ACAD INST CHEMISTRY | 2015-07-15 | — | — | CN | claimed |
| CN-1255119-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2000-05-31 | — | — | CN | claimed |
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| US-12286430-B2 | Bcl-2 inhibitor | BEIGENE, LTD. (KY) | 2025-04-29 | — | — | US | disclosed |
| US-20240376097-A1 | BCL-2 Inhibitor | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| CN-116969936-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969937-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-0129478-B1 | 2-SULFAMOYLBENZO (B) THIOPHENE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1990-01-17 | — | — | EP | disclosed |
| US-4788192-A | TOPICALLY APPLYING; FOR GLAUCOMA | MERCK & CO., INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4668697-A | Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor | MERCK & CO., INC. (US) | 1987-05-26 | — | — | US | disclosed |
| US-4664693-A | POSTEMERGENCE | ICI AUSTRALIA LIMITED (AU) | 1987-05-12 | — | — | US | disclosed |
| US-4611059-A | THROMBOXANE A2(TXA2) SYNTHETASE INHIBITORS | THE UPJOHN COMPANY (US) | 1986-09-09 | — | — | US | disclosed |
| EP-0129478-A2 | 2-Sulfamoylbenzo (b) thiophene derivatives, their preparation and pharmaceutical composition for the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | disclosed |
| EP-0125059-A2 | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1984-11-14 | — | — | EP | disclosed |
| EP-0069521-A2 | Pyridinyl and imidazolyl derivatives of benzofurans and benzothiophenes | THE UPJOHN COMPANY (US) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | CYP2A6 3337/4885ALDH1A1 2918/4885DYRK1A 2763/4885 |
| US-20240376097-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | CYP2A6 3337/4885ALDH1A1 2918/4885DYRK1A 2763/4885 |
| US-12286430-B2 | Bcl-2 inhibitor | BCL2, BCL2A1, BCL2L1 | CYP2A6 3337/4885ALDH1A1 2918/4885DYRK1A 2763/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | CYP2A6 2198/4885ALDH1A1 1093/4885DYRK1A 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.